The role of osteoprotegerin and witamin D in thyroid pathology;Rola osteoprotegeryny i witaminy D w patologii tarczycy

Endokrynologia Polska

Volumn 60, Issue 6, 2009, Pages 470-475

  Tuchendler, Dominika ^a   Bolanowski, Marek ^b  

^a Szpital Wojskowy ^*  (Poland)

^b Katedra i Klinika Endokrynologii   (Poland)

Author keywords

Hyperthyroidism; Hypothyroidism; Osteoptotegerin; Vitamin D

Indexed keywords

COLECALCIFEROL; LIOTHYRONINE; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; THYROTROPIN; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; VITAMIN D RECEPTOR;

BODY MASS; BONE DENSITY; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IN VITRO STUDY; LIOTHYRONINE BLOOD LEVEL; PATHOPHYSIOLOGY; REVIEW; THYROID DISEASE; THYROTROPIN BLOOD LEVEL;

ANIMALS; BONE AND BONES; HUMANS; OSTEOPROTEGERIN; THYROID DISEASES; THYROID HORMONES; VITAMIN D;

EID: 76149104249     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Boyce B, Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep 2007; 5: 98-104.
2. Boyce B, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008; 473: 139-146.
3. Anderson P, May B, Morris H. Vitamin d metabolism: new concepts and clinical implications. Clin Biochem Rev 2003; 24: 13-26.
4. Kobayashi Y, Udagawa N, Takahashi N. Action of RANKL and OPG for osteoklastogenesis. Crit Rev Eukaryot Gene Expo 2009; 19: 61-72.
5. Chen T, Feng X. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors. Assay Drug Dev Technol 2006; 4: 473-482.
6. Vega D, Maalouf N, Sakhaee K. The role of RANK/RANKL/OPG: clinical implications. J Clin Endocrinol Metab 2007; 92: 4514-4521.
7. Indridason O, Franzson L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporosis Int 2005; 16: 417-423.
8. Saggese G, Baroncelli G, Bertelloni S. Osteoporisis in children and adolescents: diagnosis, risk factors and prevention. J Pediatr Endocrinol Metab 2001; 14: 833-859.
9. Hofbauer L, Schoppet M. Clinical implications of the osteoprotegerin/ /RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490-195.
10. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999; 256: 449-455.
11. Suda T, Takahashi N, Udagawa N i wsp. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-357.
12. Allain T, McGregor A. Thyroid hormones and bone. J Endocrinol 1993; 139: 8-18.
13. Bassett J, Williams G. The molecular actions of thyroid hormone in bone. Trends Endocrinol Metab 2003; 14: 356-364.
14. Lakatos P. Thyroid Hormones: Beneficial or Deleterious for Bone? Calcif Tissue Int 2003; 73: 205-209.
15. Murphy E, Williams G. The thyroid and the skeleton. Clin Endocrinol (Oxf) 2004; 61: 285-298
16. Cummings S, Nevitt M, Browner W i wsp. Risk factors of hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332: 767-773.
17. Vestergaard P, Rejnmark I, Weeke J i wsp. Fracture risk in patients treated for hyperthyroidism. Thyroid 2000; 10: 341-348.
18. Vestergaard P, Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16249 patients. Thyroid 2002; 12: 411-419.
19. Harvey C, O'Shea P, Scott A i wsp. Molecular mechanism of thyroid hormone effects on bone growth and function. Molecular Genetics and Metabolism 2002; 75: 17-30.
20. Jastrup B, Mosekilde L, Melsen F i wsp. Serum levels of vitamin D metabolites and bone remodeling in hyperthyroidism. Metabolism 1982; 31: 126-132.
21. Rosen C, Adler R. Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab 1992; 75: 1531-1534.
22. Grant D, McMurdo M, Mole P i wsp. Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women? Clin Endocrinol 1995; 43: 339-345.
23. Kim I, Otto F, Zabel B i wsp. Regulation of chondrocyte differentiation by Cbfa1. Mech Dev 1999; 80: 159-170.
24. Siddiqi A, Burrin J, Wood D i wsp. Tri-iodothyronine regulates the production of interleukin-6 and interleukin-8 in human bone marrow stromal and osteoblast-like cells. J Endocrinol 1998; 157: 453-461.
25. Hofbauer L, Kluger S, Kuhne C i wsp. Detection and characterization of RANK ligand and osteoprotegerin in thyroid gland. J Cell Biochem 2002; 86: 642-650.
26. Heymann M, Riet A, Le Goff B i wsp. OPG, RANK and RANK ligand expression in thyroid lesions. Regulatory peptides 2008; 148: 46-53.
27. Amato G, Mazziotti G, Sorvillo F i wsp. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 2004; 35: 785-791.
28. Abe E, Marians R, Yu W i wsp. TSH is a negative regulator of skeletal remodeling. Cell 2003; 115: 129-130.
29. Nagasaki T, Inaba M, Jono S i wsp. Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. Eur J Endocrinol 2005; 152: 347-353.
30. Mochizuki Y, Banda N, Hattori Y i wsp. Correlation between serum osteoprotegerin and biomarkers of bone metabolism during anti-thyroid treatment in patients with Grave's disease. Horm Res 2006; 66: 236-239.
31. Mikosch P, Igerc I, Kudlacek S i wsp. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer. Eur J Clin Investig 2006; 36: 566-573.
32. Kisakol G, Kaya A, Gonen S i wsp. Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J 2003; 50: 657-666.
33. Varga F, Spitzer S, Klaushofer K. Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25 D3) inversely regulate OPG gene expression in dependence of the osteooblastic phenotype. Calcif Tissue Int 2004; 74: 382-387.
34. Guang-da X, Hiu-ling S, Zhi-song C i wsp. Change in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. J Clin Endocrinol Metab 2005; 90: 5765-5768.
35. Olkawa M, Kushida K, Takahashi M i wsp. Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time. Clin Endocrinol 1999; 50: 171-176.
36. Isaia G, Roggia C, Gola D i wsp. Bone turnover in hyperthyrioidism before and after thyrostatic management. J Endocrinol Invest 2000; 23: 727-731.
37. Pantazi H, Papapetrou P. Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J Clin Endocrinol Metab 2000; 85: 1099-1106.
38. Kalin A, Colak O, Alatas O i wsp. Bone remodelling markers and serum cytokines in patients with hyperthyriodism. Clin Endocrinol 2002; 57: 125-129.
39. Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. Wien Klin Wochenschr 2003; 115: 291-297.
40. Giusti M, Cecoli F, Fazzuoli L i wsp. Serum osteoprptegerin and soluble receptor of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study. Metabolism 2007; 56: 699-707.
41. MacFarlane I, Mawer E, Berry J i wsp. Vitamin D metabolism in hyperthyroidism. Clin Endocrinol (Oxf) 1982; 17: 51-59.
42. Barsony J, Lakatos P, Foldes J i wsp. Effect of vitamin D3 loading and thyroid hormone replacement therapy on the decreased serum 25-hydroxyvitamin D level in patients with hypothyroidism. Acta Endocrinol 1986; 113: 329-334.
43. Baeke F, Etten E, Gysemans C i wsp. Vitamin D signaling in immune-mediated disorders: Evolving insights and therapeutic opprtunities. Mol Aspects Med 2008; 29: 376-387.
44. Cantorna M, Mahon B. D-hormone and the immune system. J Rheumatol Supl. 2005; 76: 11-20.
45. Pani M, Regulla K, Segni M i wsp. A polymorphism within the vitamin d-binding protein gene is associated with Grave's disease but not with Hashimoto's thyroiditis. J Clin Endocrinol Metab 2002; 87: 2564-2567.